Sun Pharmaceutical Industries, Inc. v. Cipher Pharmaceuticals, Inc.
- Victor Marrero
- 1:25-cv-08353
- U.S. District Court · Southern District of New York
- 18
Counsel of record per CourtListener. Firm names are approximate.
In Sun Pharmaceutical v. Cipher, Judge Marrero denied Sun’s partial-vacatur request and confirmed Cipher’s arbitration award.
Sun Pharmaceutical Industries, Inc. and Cipher Pharmaceuticals, Inc. Sun’s arbitration challenge was rejected, while Cipher received confirmation and enforcement of the award, monetary judgment, interest, a Canadian royalty, and recognition of its ownership of specified clinical studies and data.
What happened
Sun Pharmaceutical Industries, Inc. v. Cipher Pharmaceuticals, Inc. concerned Sun’s effort to partially undo an arbitration award involving Absorica data. Cipher said Sun breached the parties’ 2022 agreement by submitting Cipher’s clinical data to Canadian regulators, while Sun argued it owned the data and could use it worldwide.
The arbitrator found that Cipher owned the data, that Sun’s use breached the agreement, and that Cipher was entitled to damages, arbitration fees and expenses, and a Canadian royalty. Sun argued that the arbitrator improperly used outside evidence to interpret clear contract language and had disregarded the law.
Judge Victor Marrero denied Sun’s petition and motion to partially vacate the award and granted Cipher’s request to confirm it. The court entered judgment for the arbitration amounts, awarded interest and the royalty, confirmed Cipher’s ownership of the specified clinical studies and data, and denied Cipher’s request for fees and costs from the federal court proceeding.
The detailed version
- Sun Pharmaceutical Industries, Inc. v. Cipher Pharmaceuticals, Inc. · No. 1:25-cv-08353
- Victor Marrero
- Aug. 20, 2026
Background
Sun Pharmaceutical Industries, Inc. and Cipher Pharmaceuticals, Inc. had a commercial relationship involving Absorica, an oral prescription medication used to treat acne. Cipher developed Absorica, and Sun distributed it in the United States under the parties’ 2022 distribution agreement. Sun was the successor to Ranbaxy Laboratories Inc., which Sun acquired in 2017.
The parties’ earlier agreements addressed ownership of Absorica’s New Drug Application and related clinical data. In 2022, Sun submitted an application to Health Canada for approval of Absorica LD, a low-dose version of Absorica, and included data from Cipher’s clinical trials. Cipher then began arbitration, claiming that Sun’s submission breached the 2022 agreement and that Sun’s permission to use the data was limited to marketing Absorica in the United States.
Sun denied breaching the agreement. It argued that the earlier 2012 agreement had transferred ownership of the Absorica data to Sun, allowing Sun to use the data anywhere in the world.
Arbitration award
The arbitrator found that the 2022 agreement did not transfer ownership of the data. The arbitrator examined the 2012 agreement, letters to the Food and Drug Administration, and expert testimony concerning whether Sun already owned the data. The arbitrator interpreted the 2012 agreement’s reference to the Food and Drug Administration’s regulation on transferring a New Drug Application as limiting Sun’s use of the data to the United States.
The arbitrator concluded that Cipher owned the Absorica data and that Sun breached the 2022 agreement by submitting it to Health Canada. The award gave Cipher CAD 4,242,360 in compensatory damages and USD 2,171,671.45 in attorneys’ fees, costs, and expenses connected with the arbitration. It also awarded Cipher a 15 percent royalty on defined net sales of Absorica LD in Canada from January 1, 2026, through December 31, 2040.
Sun’s request to vacate part of the award
Sun asked the court to partially vacate, or set aside, the portion of the award concerning breach of the 2022 agreement. Sun argued that the arbitrator had committed a “manifest disregard of the law,” a narrow ground for overturning an arbitration award, by using outside evidence to interpret agreements that the arbitrator had found unambiguous.
The court rejected that argument. It explained that an arbitrator’s alleged misuse of outside evidence to apply New York’s contract-interpretation rules does not by itself amount to manifest disregard of the law. The court also said that, even if such misuse could support vacatur, Sun’s challenge would fail because the arbitrator ultimately relied on the text of the 2012 agreement and the relevant federal regulation.
The court emphasized that judicial review of an arbitration award is highly limited. It held that the arbitrator had provided at least a minimally reasonable explanation for the result, and that the court could not overturn the arbitrator merely because Sun disagreed with the contract interpretation. The court therefore denied Sun’s petition and motion to partially vacate the award.
Confirmation, judgment, and interest
Cipher cross-petitioned to confirm the arbitration award. Because the court denied Sun’s challenge, it granted Cipher’s cross-petition and entered the confirmed award as a judgment of the court.
The judgment included CAD 4,242,360 in compensatory damages and USD 2,171,671.45 in arbitration attorneys’ fees and expenses. The court also awarded post-award, prejudgment interest at nine percent annually from August 20, 2025, through entry of judgment, calculated on both figures. Cipher was also awarded the 15 percent Canadian royalty and was declared the owner of the clinical studies and data listed in section 5.2 of FDA New Drug Application 21-951.
The court ordered post-judgment interest at the statutory rate under 28 U.S.C. § 1961 from entry of judgment until payment. Cipher’s separate request for attorneys’ fees and costs incurred in the federal court proceeding was denied because Cipher had not submitted records supporting the amount and reasonableness of that request. The court directed the Clerk to close the case.
Read the full 18-page opinion on CourtListener, the free public archive maintained by the Free Law Project.